TauRx Presents at the Royal Society of Medicine
TauRx Presents at the Royal Society of Medicine
Professor Claude Wischik, CEO and co-founder of TauRx, presented at the final session of a four-part webinar series on dementia for the Royal Society of Medicine 26 May 2021.
The session examined the role of the tau tangle in the pathophysiology of Alzheimer's disease and the anticipated impact of a novel therapeutic approach in late-stage development followed by an engaging panel session.
Quick off the mark, one participant wrote "I’ve just listened to the most fantastic talk hosted by the RSM by Professor Claude Wischik and he mentioned that this poster was available." A dedicated educational website on tau pathology, with several free downloadable resources, can be accessed here www.targetingtau.com or by clicking here
Recent News
LUCIDITY phase 3 topline data presented at CTAD for HMTM - the only oral anti-Tau therapy in late-stage development
Dec 02, 2022
TauRx Announces Additional Investment of USD119 million following announcement of Phase 3 LUCIDITY Topline Results
Nov 14, 2022
TauRx Pharmaceuticals Ltd has announced further results from its Phase 3 LUCIDITY trial for Hydromethylthionine mesylate (HMTM)
Oct 06, 2022
TauRx Pharmaceuticals Ltd is delighted to name Dr Richard Stefanacci, an established global key opinion leader in Alzheimer’s, as Chief Medical Officer (CMO)
Oct 06, 2022